Tags

Type your tag names separated by a space and hit enter

Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
Clin Infect Dis. 2003 Nov 01; 37(9):1216-25.CI

Abstract

An observational study was performed involving 95 children with vertically transmitted human immunodeficiency virus type 1 infection to assess the sustainability of undetectable viral loads (VLs) and increased CD4+ T lymphocyte percentages after 48 months of highly active antiretroviral therapy (HAART). The median time to achieve a 10% increase in the CD4+ T lymphocyte percentage was 11.01 months. The median time to achieve an undetectable VL was 6.4 months. At the end of the study, 64.2% of the children had achieved an undetectable VL. Of the patients with an initial VL of >3.6 log10 copies/mL, 74.7% had a decrease in the VL of 1 log10 copies/mL. By contrast, of the patients who presented with an initial VL of >4.6 log10 copies/mL, 37.9% had a decrease of >2 log10 copies/mL. Higher VL at baseline, antiretroviral therapy regimens received before HAART, and multiple drug switches while receiving antiretroviral therapy were all inversely associated with an undetectable VL. A CD4+ T lymphocyte percentage of >25% was directly associated with undetectable VL during the follow-up period. In conclusion, first-line HAART induces beneficial virological and immunological outcome responses in children.

Authors+Show Affiliations

Laboratory of Immuno-Molecular Biology, Hospital Gregorio Marañón, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14557967

Citation

Resino, Salvador, et al. "Viral Load and CD4+ T Lymphocyte Response to Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Children: an Observational Study." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 37, no. 9, 2003, pp. 1216-25.
Resino S, M Bellón J, Gurbindo D, et al. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clin Infect Dis. 2003;37(9):1216-25.
Resino, S., M Bellón, J., Gurbindo, D., Tomás Ramos, J., Antonio León, J., Jose Mellado, M., & Angeles Muñoz-Fernández, M. (2003). Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 37(9), 1216-25.
Resino S, et al. Viral Load and CD4+ T Lymphocyte Response to Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Children: an Observational Study. Clin Infect Dis. 2003 Nov 1;37(9):1216-25. PubMed PMID: 14557967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. AU - Resino,Salvador, AU - M Bellón,José, AU - Gurbindo,Dolores, AU - Tomás Ramos,José, AU - Antonio León,Juan, AU - Jose Mellado,M, AU - Angeles Muñoz-Fernández,M, Y1 - 2003/10/03/ PY - 2003/01/28/received PY - 2003/06/11/accepted PY - 2003/10/15/pubmed PY - 2003/12/3/medline PY - 2003/10/15/entrez SP - 1216 EP - 25 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 37 IS - 9 N2 - An observational study was performed involving 95 children with vertically transmitted human immunodeficiency virus type 1 infection to assess the sustainability of undetectable viral loads (VLs) and increased CD4+ T lymphocyte percentages after 48 months of highly active antiretroviral therapy (HAART). The median time to achieve a 10% increase in the CD4+ T lymphocyte percentage was 11.01 months. The median time to achieve an undetectable VL was 6.4 months. At the end of the study, 64.2% of the children had achieved an undetectable VL. Of the patients with an initial VL of >3.6 log10 copies/mL, 74.7% had a decrease in the VL of 1 log10 copies/mL. By contrast, of the patients who presented with an initial VL of >4.6 log10 copies/mL, 37.9% had a decrease of >2 log10 copies/mL. Higher VL at baseline, antiretroviral therapy regimens received before HAART, and multiple drug switches while receiving antiretroviral therapy were all inversely associated with an undetectable VL. A CD4+ T lymphocyte percentage of >25% was directly associated with undetectable VL during the follow-up period. In conclusion, first-line HAART induces beneficial virological and immunological outcome responses in children. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/14557967/Viral_load_and_CD4+_T_lymphocyte_response_to_highly_active_antiretroviral_therapy_in_human_immunodeficiency_virus_type_1_infected_children:_an_observational_study_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/378804 DB - PRIME DP - Unbound Medicine ER -